A61K 47/68033
The drug being a maytansine
Official title: {the drug being a maytansine}
A61K47/68033 (The drug being a maytansine) appears on 469 US grants and 983 published applications in this corpus.
Search patents in A61K- Granted patents
- 469
- Published applications
- 983
- Assignees
- 252
- Inventors
- 1,522
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 1 | 5 |
| 2004 | 0 | 11 |
| 2005 | 2 | 12 |
| 2006 | 2 | 11 |
| 2007 | 2 | 16 |
| 2008 | 4 | 13 |
| 2009 | 10 | 30 |
| 2010 | 8 | 13 |
| 2011 | 7 | 23 |
| 2012 | 13 | 15 |
| 2013 | 16 | 13 |
| 2014 | 17 | 45 |
| 2015 | 19 | 45 |
| 2016 | 23 | 62 |
| 2017 | 30 | 69 |
| 2018 | 28 | 62 |
| 2019 | 44 | 58 |
| 2020 | 43 | 63 |
| 2021 | 36 | 57 |
| 2022 | 36 | 72 |
| 2023 | 29 | 57 |
| 2024 | 35 | 88 |
| 2025 | 33 | 86 |
| 2026 | 26 | 55 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of treating residual breast cancer with trastuzumab emtansine22 Sep 2026US 12,740,962 B2Genentech, Inc.
- Anti-CEACAM5 antibodies and conjugates and uses thereof8 Sep 2026US 12,729,239 B2Merck Patent GmbH
- Molecules that bind to CD66e polypeptides11 Aug 2026US 12,703,760 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Diagnosis and treatment of cancer28 Jul 2026US 12,693,294 B2Rab Diagnostics AS
- Combination therapy with antibody-drug conjugates and hyaluronidases14 Jul 2026US 12,678,492 B2Halozyme, Inc.
- Slc4a1 (band 3) binding single domain antibodies for increased blood retention8 Oct 2026US 2026/0308272 A1
- Antibodies and assays for detection of folate receptor 124 Sep 2026US 2026/0286003 A1ImmunoGen, Inc.
- Site-specific orthogonal bioconjugate modality and application thereof24 Sep 2026US 2026/0286332 A1Genequantum Healthcare (Suzhou) Co., Ltd.
- Combination therapy with antibody-drug conjugates and hyaluronidases17 Sep 2026US 2026/0273030 A1Halozyme, Inc.
- Trogocytosis in cancer cells and methods for treating cancer related thereto17 Sep 2026US 2026/0274990 A1Arizona Board of Regents on Behalf of the University of Arizona
Most cited
By later US patents
- Cytotoxic agents comprising maytansinoids and their therapeutic use805US 5,208,020 AImmunoGen, Inc. · 1993
- Cytotoxic agents comprising maytansinoids and their therapeutic use515US 5,416,064 AImmunoGen, Inc. · 1995
- Cysteine engineered antibodies and conjugates485US 7,521,541 B2Genetech, Inc. · 2009
- Cytotoxic agents comprising new maytansinoids227US 7,276,497 B2ImmunoGen, Inc. · 2007
- Process for the preparation and purification of thiol-containing maytansinoids175US 6,333,410 B1ImmunoGen, Inc. · 2001